Spero Therapeutics Return on Equity

Spero Therapeutics (SPRO) currently reports a ROE of 16.7%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Spero Therapeutics's ROE history and peer comparisons.

Spero Therapeutics's ROE of 16.7% is lower than the Healthcare sector average of 21.67%. That is roughly 22.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Spero Therapeutics's current 16.7% should be judged against Healthcare norms (sector average: 21.67%) and against SPRO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 16.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Spero Therapeutics, and consider following SPRO for alerts when major investors trade the stock.

Spero Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 16.7% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRO with unrelated industries.